دورية أكاديمية
The Clinician's Interview-Based Impression of Change (Plus caregiver input) and goal attainment in two dementia drug trials: Clinical meaningfulness and the initial treatment response.
| العنوان: | The Clinician's Interview-Based Impression of Change (Plus caregiver input) and goal attainment in two dementia drug trials: Clinical meaningfulness and the initial treatment response. |
|---|---|
| المؤلفون: | Stanley J; DGI Clinical Inc., Halifax, Nova Scotia, Canada., Howlett SE; DGI Clinical Inc., Halifax, Nova Scotia, Canada.; Division of Geriatric Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.; Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada., Dunn T; DGI Clinical Inc., Halifax, Nova Scotia, Canada., Rockwood K; DGI Clinical Inc., Halifax, Nova Scotia, Canada.; Division of Geriatric Medicine, Dalhousie University, Halifax, Nova Scotia, Canada. |
| المصدر: | Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2021 May; Vol. 17 (5), pp. 856-865. Date of Electronic Publication: 2021 Apr 29. |
| نوع المنشور: | Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: John Wiley & Sons, Ltd Country of Publication: United States NLM ID: 101231978 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-5279 (Electronic) Linking ISSN: 15525260 NLM ISO Abbreviation: Alzheimers Dement Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2020- : Hoboken, NJ : John Wiley & Sons, Ltd. Original Publication: Orlando, FL : Elsevier, Inc. |
| مواضيع طبية MeSH: | Alzheimer Disease*/diagnosis , Alzheimer Disease*/drug therapy , Patient Reported Outcome Measures* , Severity of Illness Index*, Caregivers/*psychology , Cholinesterase Inhibitors/*therapeutic use , Donepezil/*therapeutic use , Galantamine/*therapeutic use , Nootropic Agents/*therapeutic use, Aged ; Clinical Trials as Topic ; Double-Blind Method ; Female ; Humans ; Male |
| مستخلص: | Introduction: The Clinician's Interview-Based Impression of Change Plus caregiver input (CIBIC-Plus) has been widely used in dementia drug trials to evaluate cognition, behavior, and function. New trials of symptomatic drugs forecast renewed interest in this measure. Methods: To test its clinical meaningfulness, we examined how CIBIC-Plus performed in two cholinesterase inhibitor trials compared to goal attainment scaling Scale (GAS) scores, a patient-reported outcome measure. Results: Net goal attainment was seen for all but one GAS domains in subjects who improved on the CIBIC-Plus. Subjects who improved initially on CIBIC-Plus scores were likely to remain improved across all other outcomes for each trial's duration, except for Disability Assessment for Dementia scores. Discussion: The initial response to treatment, as assessed by CIBIC-Plus, remained stable for most outcome measures. Even small CIBIC-Plus improvement changes are associated with clinically meaningful change as assessed by GAS. Other tests detect decline better than improvement. (© 2020 the Alzheimer's Association.) |
| References: | Cui S, Chen N, Yang M, et al. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2019;2019(11). Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev. 2018;6:CD001190. Birks JS, Grimley EJ. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2015;4:CD001191. Birks J, Craig D. Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev. 2006;1:CD004746. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's disease cooperative study-clinical global impression of change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(2):S22-S32. Cummings J, Feldman HH, Scheltens P. The “rights” of precision drug development for Alzheimer's disease. Alz Res Therapy. 2019;11(1):76. Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-562. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):280-292. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270-279. Hamuro A, Honda M, Wakaura Y. Suvorexant for the treatment of insomnia in patients with Alzheimer's disease. Aust N Z J Psychiatry. 2018;52(2):207-208. Herrmann N, Ruthirakuhan M, Gallagher D, et al. Randomized placebo-controlled trial of nabilone for agitation in Alzheimer's Disease. Am J Geriatr Psychiatry. 2019;27(11):1161-1173. Žmuc VL, Pregelj P, Jerin A. Treating agitation and aggression in patients with Alzheimer's disease with escitalopram. Psychogeriatrics. 2016;16(6):384-385. Ehrhardt Stephan, Porsteinsson Anton P., Munro Cynthia A., Rosenberg Paul B., Pollock Bruce G., Devanand Davangere P., Mintzer Jacobo, Rajji Tarek K., Ismail Zahinoor, Schneider Lon S., Baksh Sheriza N., Drye Lea T., Avramopoulos Dimitri, Shade David M., Lyketsos Constantine G., (2019) Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial. Alzheimer's & Dementia, 15 (11), 1427-1436. http://doi.org/10.1016/j.jalz.2019.06.4946. Davis DH, Muniz-Terrera G, Keage HA, et al. Association of delirium with cognitive decline in late life: a neuropathologic study of 3 population-based cohort studies. JAMA Psychiatry. 2017;74(3):244-251. Wallace LMK, Theou O, Godin J, Andrew MK, Bennett DA, Rockwood K. Investigation of frailty as a moderator of the relationship between neuropathology and dementia in Alzheimer's disease: a cross-sectional analysis of data from the rush memory and aging project. Lancet Neurol. 2019;18(2):177-184. Rockwood K, Sanon Aigbogun M, Stanley J, et al. The symptoms targeted for monitoring in a web-based tracking tool by caregivers of people with dementia and agitation: cross-sectional study. J Med Internet Res. 2019;21(6):e13360. Graf A, Risson V, Gustavsson A, et al. Assessment of clinical meaningfulness of endpoints in the generation program by the Insights to Model Alzheimer's Progression in Real Life (iMAP) Study. J Prev Alzheimers Dis. 2019;6(2):85-89. Rockwood K, Howlett SE, Hoffman D, Schindler R, Mitnitski A. Clinical meaningfulness of Alzheimer's disease assessment scale-cognitive subscale change in relation to goal attainment in patients on cholinesterase inhibitors. Alzheimers Dement. 2017;13(10):1098-1106. Siemers E, Holdridge KC, Sundell KL, Liu-Seifert H. Function and clinical meaningfulness of treatments for mild Alzheimer's disease. Alzheimers Dement. 2016;2:105-112. Sano M, Soto M, Carrillo M, et al. Identifying better outcome measures to improve treatment of agitation in dementia: a report from the EU/US/CTAD Task Force. J Prev Alzheimers Dis. 2018;5(2):98-102. Fillit H. Getting more clinically meaningful measures of functional impairment for Alzheimer's Disease. J Prev Alzheimers Dis. 2017;4(2):67-68. Joe E, Ringman JM. Cognitive symptoms of Alzheimer's disease: clinical management and prevention. BMJ. 2019;367:l6217. Fink HA, Linskens EJ, MacDonald R, et al. Benefits and harms of prescription drugs and supplements for treatment of clinical alzheimer-type dementia: a systematic review and meta-analysis. Ann Intern Med. 2020;10. Rockwood K, Stolee P, Howard K, Mallery L. Use of goal attainment scaling to measure treatment effects in an anti-dementia drug trial. Neuroepidemiology. 1996;15(6):330-338. Bogardus ST Jr, Bradley EH, Tinetti ME. A taxonomy for goal setting in the care of persons with dementia. J Gen Intern Med. 1998;13(10):675-680. Hartman D, Borrie MJ, Davison E, Stolee P. Use of Goal Attainment Scaling in a dementia special care unit. Am J Alzheimer's Dis. 1997;12(3):111-116. Kiresuk TJ, Sherman RE. Goal attainment scaling: a general method for evaluating comprehensive community mental health programs. Community Ment Health J. 1968;4:443-453. Rockwood K, Graham JE, Fay S. ACADIE investigators. Goal setting and attainment in Alzheimer's disease patients treated with donepezil. J Neurol Neurosurg Psychiatry. 2002;73(5):500-507. Rockwood K, Fay S, Song X, MacKnight C, Gorman M; Video-Imaging Synthesis of Treating Alzheimer's Disease (VISTA) Investigators. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial. CMAJ. 2006;174(8):1099-1105. Cook C, Fay S, Rockwood K. Decreased initiation of usual activities in people with mild-to-moderate Alzheimer's disease: a descriptive analysis from the VISTA clinical trial. Int Psychogeriatr. 2008;20(5):952-963. Cook C, Fay S, Rockwood K. Verbal repetition in people with mild-to-moderate Alzheimer Disease: a descriptive analysis from the VISTA clinical trial. Alzheimer Dis Assoc Disord. 2009;23(2):146-151. Perc M. The Matthew effect in empirical data. J R Soc Interface. 2014;11:20140378. Rockwood K, MacKnight C. Assessing the clinical importance of statistically significant improvement in anti-dementia drug trials. Neuroepidemiology. 2001;20(2):51-56. Urach S, Gaasterland C, Posch M, et al. Statistical analysis of Goal Attainment Scaling endpoints in randomized trials. Stat Methods Med Res. 2019;28(6):1893-1910. Gaasterland CMW, van der Weide MCJ, Roes KCB, van der Lee JH. Goal Attainment Scaling as an outcome measure in rare disease trials: a conceptual proposal for validation. BMC Med Res Methodol. 2019;19(1):227. Olin JT, Schneider LS, Doody RS, et al. Clinical evaluation of global change in Alzheimer's disease: identifying consensus. J Geriatr Psychiatry Neurol. 1996;9(4):176-180. Boyle PA, Yu L, Leurgans SE, et al. Attributable risk of Alzheimer's dementia attributed to age-related neuropathologies. Ann Neurol. 2019; 85(1):114-124. Wilson RS, Yu L, Leurgans SE, Bennett DA, Boyle PA. Proportion of cognitive loss attributable to terminal decline. Neurology. 2020;94(1):e42-e50. Wallace LMK, Theou O, Godin J, et al. Investigation of frailty as a moderator of the relationship between neuropathology and dementia in Alzheimer's disease: a cross-sectional analysis of data from the rush memory and aging project. Lancet Neurol. 2019;18(2):177-184. Wissler Gerdes EO, Zhu Y, Tchkonia T, Kirkland JL. Discovery, development, and future application of senolytics: theories and predictions. FEBS J. 2020;1287(12):2418-2427. Rockwood K, Wallack M, Tallis R. The treatment of Alzheimer's disease: success short of cure. Lancet Neurol. 2003;2(10):630-633. |
| معلومات مُعتمدة: | Canada CIHR |
| فهرسة مساهمة: | Keywords: ADAS-cog; Alzheimer's disease; CIBIC-Plus; clinical trials; goal attainment scaling; symptomatic treatment |
| المشرفين على المادة: | 0 (Cholinesterase Inhibitors) 0 (Nootropic Agents) 0D3Q044KCA (Galantamine) 8SSC91326P (Donepezil) |
| تواريخ الأحداث: | Date Created: 20210430 Date Completed: 20211110 Latest Revision: 20211110 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1002/alz.12242 |
| PMID: | 33928754 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1552-5279 |
|---|---|
| DOI: | 10.1002/alz.12242 |